The activating KRAS<sup>G12C</sup> mutation, in particular, is a key driver in a significant percentage of non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and lung adenocarcinoma. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.